We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SYGNIS AG Installs Scalable Production Capability for Lightning-Link Antibody Conjugation Technology
Product News

SYGNIS AG Installs Scalable Production Capability for Lightning-Link Antibody Conjugation Technology

SYGNIS AG Installs Scalable Production Capability for Lightning-Link Antibody Conjugation Technology
Product News

SYGNIS AG Installs Scalable Production Capability for Lightning-Link Antibody Conjugation Technology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "SYGNIS AG Installs Scalable Production Capability for Lightning-Link Antibody Conjugation Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SYGNIS AG announced it has extended the manufacturing capability for its Lightning-Link® technology, currently marketed under the Innova Biosciences brand, to support scalability and bulk production of antibodies.

Lightning-Link is an innovative technology that enables direct labeling of antibodies or proteins in as little as 20 minutes, for use in R&D applications, drug discovery and the development of diagnostic kits. Lightning-Link kits are the world’s fastest, easiest to use and most efficient method of labeling antibodies or proteins, requiring only 30 seconds hands-on time, and there are no separation steps involved, meaning 100% of materials are retained.

The increased manufacturing capability means the Company is now able to offer the Lightning-Link product range in volumes from 10µg to 100mg, in single reaction vials tested with Rabbit IgG in ELISA. For antibody manufacturers that have fixed internal processes for conjugation, bulk supply of ultra-high quality raw materials and labels that are used in the Lightning-Link kits are also available.

Alastair Carrington, VP Business Development & Marketing, Innova Biosciences, commented:
“The ability to further support antibody manufacturers at both small and large scale, including those requiring bulk raw materials to work with historic standard operating procedures, provides the opportunity to reach new, high value markets. Access to Lightning-Link technology will enable manufacturers to dramatically increase their conjugate portfolios, whilst retaining batch-to-batch consistency.”

All raw materials used in Lightning-Link kits are manufactured from natural sources, grown in continuous microalgae culture, providing assurance of high quality purification with extreme quantum efficiency and excellent stability.
Advertisement